Combretastatin A4 is a potent tubulin polymerization inhibitor and antiangiogenic agent primarily used in oncology research to target and disrupt tumor blood vessel formation. By interfering with microtubule… Read more
Combretastatin A4 is a potent tubulin polymerization inhibitor and antiangiogenic agent primarily used in oncology research to target and disrupt tumor blood vessel formation. By interfering with microtubule dynamics, this compound induces endothelial cell apoptosis and inhibits tumor neovascularization, making it a critical subject in experimental cancer therapeutics. Laboratories analyzing this agent require high-quality reference standards for rigorous analytical testing, method validation, and quality control. This category includes stable isotope labelled compounds, such as deuterium-labelled and carbon-13 variants, which are essential for precise quantification via mass spectrometry. These labelled standards act as internal controls, allowing researchers to overcome matrix effects and improve accuracy during impurity profiling and pharmacokinetic studies. By providing reliable reference materials, these compounds support the validation of analytical methods required for consistent and reproducible results in the development and characterization of tubulin-targeting therapies.